Over the next three years the pharma company plans to build a $500 million complex on its new campus that will house its U.K. operations for biologics and small molecule research as well as the corporate staff now operating in London.
AstraZeneca's first-quarter earnings report was a stark indication of why its new CEO Pascal Soriot is scrambling to buy some new drugs the company can lean on.
Determined to prove to investors that AstraZeneca has a late-stage game plan that can rescue the pharma company from a lengthy losing streak, the company today spotlighted plans to speed up the Phase III development timeline on three key cancer drugs.
The U.K.'s struggling AstraZeneca is not only looking to media that is social to develop some kind of relationship with patients; it has gone local as well.
AstraZeneca today had another big round of dismal revenue numbers to explain today. With generic rivals tearing at some of its key franchises, the pharma giant reported a 13% drop in revenue for the first quarter.
At least one big AstraZeneca shareholder isn't concerned about CEO Pascal Soriot's pay package.
While AstraZeneca's busy business development team was fashioning a new discovery deal with Bind Therapeutics in Cambridge, MA, it was also polishing a pact in the other Cambridge.
CEO pay in Europe continues to be a flashpoint given the high unemployment and austerity measures the workaday folk on the continent face. Still, a new analysis shows the CEO's of European drugmakers continue to pull in far less than their U.S. counterparts.
Some U.K.pension funds are none too happy about AstraZeneca's special bonus for its new CEO, Pascal Soriot.
Standard & Poor's is not impressed with AstraZeneca's jump-start plan. The ratings agency cut the U.K.-based drugmaker's credit ratings, citing CEO Pascal Soriot 's strategy update last month.